The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York 503A Vs. 503B Compounding Pharmacies: Similarities & Differences Why the FDA Is Paying More Attention to 503A & 503B Pharmacies If you've been watching the compounding space, especially around GLP 1s and peptides, you've probably noticed something. The FDA is paying 503A vs. 503B Compounding & FDA Regulations Guide Restore Health Consulting BPC 157, Semaglutide, And Wellness Peptides: What's Actually Allowed In California? Holt Law